5681-36-7

Usage

Uses

Used in Cancer Treatment:
1,2-DIHEXADECANOYL-RAC-GLYCERO-3-PHOSPHOETHANOLAMINE is used as a luminescence marker in enhancing radiotherapy for cancer treatment. Its ability to emit light upon exposure to specific wavelengths makes it a valuable tool in improving the effectiveness of radiation therapy. By serving as a marker, it helps in the precise targeting of cancer cells, thereby minimizing damage to healthy tissues and enhancing the overall therapeutic outcome.
Used in Pharmaceutical Industry:
1,2-DIHEXADECANOYL-RAC-GLYCERO-3-PHOSPHOETHANOLAMINE is used as a luminescence marker for drug delivery and tracking. Its unique optical properties allow researchers to monitor the distribution and accumulation of drug carriers within the body. This capability is particularly useful in the development of targeted drug delivery systems, where the efficiency and safety of the treatment can be closely monitored.
Used in Biomedical Research:
1,2-DIHEXADECANOYL-RAC-GLYCERO-3-PHOSPHOETHANOLAMINE is used as a luminescence marker in various biomedical research applications. Its ability to emit light makes it an ideal tool for studying cellular processes, such as membrane dynamics, lipid metabolism, and cell signaling. Additionally, it can be used in the development of biosensors and imaging techniques to visualize biological events at the molecular level.

InChI:InChI=1/C37H74NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-36(39)43-33-35(34-45-47(41,42)44-32-31-38)46-37(40)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h35H,3-34,38H2,1-2H3,(H,41,42)

Upstream product

• 19971-21-2 Silver Benzyl 2,3-Di-O-palmitoyl-D,L-glycerol 1-Phosphate 
• 623-65-4 palmitic anhydride 
• 26849-38-7 phosphoric acid-(2,3-bis-palmitoyloxy-propyl ester)-(2-phthalimido-ethyl ester) 
• 19805-08-4 D,L-1,2-Di-O-palmitoyl-glycerin-3-phosphorsaeure-<2-tritylamino-ethylester>-benzylester 
• 107117-99-7 DL-1,2-Di-O-palmitoyl-glycerin-3-phosphorsaeurebenzylester-<2-tritylamino-ethylester>-Na-Salz 

Downstream Products

• 94483-00-8 Hexadecanoic acid 1-hexadecanoyloxymethyl-2-{hydroxy-[2-(trityl-amino)-ethoxy]-phosphoryloxy}-ethyl ester 
• 126695-59-8 4-(hydroxymethyl)-2,3,5,6-tetrafluorophenyl azide 
• 94451-78-2 Hexadecanoic acid 2-{[2-(4-bromo-phenyl)-2-oxo-ethoxy]-[2-(3-{(S)-1-carboxy-2-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-ethylcarbamoyl}-propionylamino)-ethoxy]-phosphoryloxy}-1-hexadecanoyloxymethyl-ethyl ester 
• 94451-75-9 (2R,4S)-2-[(R)-(2-{(2,3-Bis-hexadecanoyloxy-propoxy)-[2-(4-nitro-phenyl)-ethoxy]-phosphoryloxy}-ethylcarbamoyl)-phenylacetylamino-methyl]-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-(4-bromo-phenyl)-2-oxo-ethyl ester 
• 94451-74-8 (2R,4S)-2-[(R)-(2-{(2,3-Bis-hexadecanoyloxy-propoxy)-[2-(4-bromo-phenyl)-2-oxo-ethoxy]-phosphoryloxy}-ethylcarbamoyl)-phenylacetylamino-methyl]-5,5-dimethyl-thiazolidine-4-carboxylic acid 2-(4-bromo-phenyl)-2-oxo-ethyl ester 
• 94491-16-4 Hexadecanoic acid 2-{[2-(3-{(S)-1-carboxy-2-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-ethylcarbamoyl}-propionylamino)-ethoxy]-hydroxy-phosphoryloxy}-1-hexadecanoyloxymethyl-ethyl ester 
• 94451-71-5 Hexadecanoic acid 1-hexadecanoyloxymethyl-2-{[2-(4-nitro-phenyl)-ethoxy]-[2-(trityl-amino)-ethoxy]-phosphoryloxy}-ethyl ester 
• 94451-72-6 Hexadecanoic acid 2-{[2-(4-bromo-phenyl)-2-oxo-ethoxy]-[2-(trityl-amino)-ethoxy]-phosphoryloxy}-1-hexadecanoyloxymethyl-ethyl ester 
• 94451-76-0 (2R,4S)-2-((R)-{2-[(2,3-Bis-hexadecanoyloxy-propoxy)-hydroxy-phosphoryloxy]-ethylcarbamoyl}-phenylacetylamino-methyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 
• 94451-77-1 Hexadecanoic acid 2-{[2-(4-bromo-phenyl)-2-oxo-ethoxy]-[2-(3-carboxy-propionylamino)-ethoxy]-phosphoryloxy}-1-hexadecanoyloxymethyl-ethyl ester 
• 102932-38-7 Hexadecanoic acid 2-{(2-tert-butoxycarbonylamino-ethoxy)-[2-(4-nitro-phenyl)-ethoxy]-phosphoryloxy}-1-hexadecanoyloxymethyl-ethyl ester 

Relevant academic research and scientific papers

Novel lung intelligent drug release system

The invention discloses a novel lung intelligent drug release system which comprises a targeted structure and a polypeptide adaptor, wherein the targeted structure is multivalent long-chain fatty acylphospholipid capable of being subjected to specific identification by a lung epithelial cell surface receptor SP-A; the polypeptide adaptor is used for connecting a drug with the targeted structure and is a polypeptide chain which can be specially hydrolyzed by specific protease; and the specific protease is expressed a lot only when lung cells have pathological features. According to the invention, the long-chain fatty acyl phospholipid is used as a specifically identified group so as to mediate cells to generate endocytosis, macromolecules in nucleic acid drugs or polypeptide drugs, which are difficult to pass through cell membranes, can be transferred into cells, and polypeptide which can be hydrolyzed by the specific protease expressed a lot at lung lesion sites is combined and used as the adaptor, so that the novel drug release system can enter lung cells in a targeted mode and intelligently identify the lung lesion sites to release the drug.

Solid-Phase Phosphatidylethanolamine Synthesis

Dipalmitoylphosphatidylethanolamine (DPPE) was prepared from natural phosphatidylethanolamine (cephalin) and palmitic anhydride (PAh) by using polymer-supported trityl as a protective group for the amino group of cephalin.

Composition and method for treatment of disseminated fungal infections in mammals

A method is disclosed for treatment of disseminated fungal infection in a mammal comprising the administration of a fungicidally effective amount of Amphotericin B encapsulated in a substantially sterol-free liposome to the infected mammal. Also provided is an agent for treatment of disseminated fungal infection in a mammal comprising Amphotericin B encapsulated in a liposome which consists essentially of lipids other than sterols.